Monte Rosa Therapeutics (GLUE) FCF Margin (2024 - 2026)
Monte Rosa Therapeutics' (GLUE) quarterly FCF Margin came in at 932.67% in Q1 2026, down 87875.0% year-on-year from N/an in Q1 2025, and up 39.29% quarter-over-quarter from 1536.28% in Q4 2025.
Monte Rosa Therapeutics (GLUE) FCF Margin (2024 - 2026) Analysis & Trends
Monte Rosa Therapeutics' FCF Margin history runs 3 years deep, the most recent figure standing at 932.67% for Q1 2026.
- On a quarterly basis, FCF Margin fell 87875.0% year-over-year to 932.67% in Q1 2026; TTM through Mar 2026 was 401.3%, a 42343.0% decrease from a year earlier, with the FY2025 full-year figure at 18.55%, down 7402.0% from the prior year.
- FCF Margin advanced to 932.67% in Q1 2026 per GLUE's latest filing, from 1536.28% in the prior quarter.
- Across five years, FCF Margin topped out at 218.77% in Q4 2024 and bottomed at 3679.32% in Q1 2024.
- The 3-year median for FCF Margin is 232.13% (2024), against an average of 757.4%.
- Biggest YoY gain for FCF Margin was 362540 bps in 2025; the steepest drop was 175505 bps in 2025.
- Year by year, FCF Margin stood at 218.77% in 2024, then sank by 802 bps to 1536.28% in 2025, then jumped by 39 bps to 932.67% in 2026.
- Per Business Quant, the three latest GLUE FCF Margin figures stand at 932.67% (Q1 2026), 1536.28% (Q4 2025), and 68.85% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Monte Rosa Therapeutics | 2.30 Bn | 1.62 Bn | - | -932.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -932.67% |
| Dec 31, 2025 | -1,536.28% |
| Sep 30, 2025 | 68.85% |
| Jun 30, 2025 | -26.89% |
| Mar 31, 2025 | -53.92% |
| Dec 31, 2024 | 218.77% |
| Sep 30, 2024 | -232.13% |
| Jun 30, 2024 | -643.02% |
| Mar 31, 2024 | -3,679.32% |